pembrolizumab
merck
['pembro']
for patients who complete 2y of pembrolizumab, 3y os rate (after completing 2y pembro) was 70% - though not all of those patients are cured (44% were alive without pd or subsequent therapy). #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him